Alpha Teknova, Inc.TKNOEarnings & Financial Report
Alpha Teknova, Inc. is a life sciences company that develops and manufactures specialized reagents, cell culture media, and custom laboratory solutions. It serves biopharmaceutical, molecular diagnostic, and academic research clients, primarily operating across the North American market to support drug discovery, diagnostic testing, and life science research workflows.
TKNO Q4 FY2025 Key Financial Metrics
Revenue
$10.0M
Gross Profit
$3.2M
Operating Profit
$-4.6M
Net Profit
$-4.8M
Gross Margin
32.5%
Operating Margin
-46.2%
Net Margin
-47.7%
YoY Growth
7.8%
EPS
$-0.08
Alpha Teknova, Inc. Q4 FY2025 Financial Summary
Alpha Teknova, Inc. reported revenue of $10.0M (up 7.8% YoY) for Q4 FY2025, with a net profit of $-4.8M (up 16.8% YoY) (-47.7% margin). Cost of goods sold was $6.7M, operating expenses totaled $7.9M.
Key Financial Metrics
| Total Revenue | $10.0M |
|---|---|
| Net Profit | $-4.8M |
| Gross Margin | 32.5% |
| Operating Margin | -46.2% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Alpha Teknova, Inc. Q4 FY2025 revenue of $10.0M breaks down across 3 segments, led by Lab Essentials at $6.8M (68.4% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Lab Essentials | $6.8M | 68.4% |
| Clinical Solutions | $2.7M | 27.3% |
| Other | $435.0K | 4.4% |
Alpha Teknova, Inc. Revenue by Segment — Quarterly Trend
Alpha Teknova, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Lab Essentials and Clinical Solutions) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Lab Essentials | $6.8M | $8.3M | $7.8M | $8.1M |
| Clinical Solutions | $2.7M | $1.7M | $2.1M | $1.2M |
| Other | $435.0K | $440.0K | $435.0K | $516.0K |
Alpha Teknova, Inc. Annual Revenue by Year
Alpha Teknova, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $40.5M).
Alpha Teknova, Inc. Quarterly Revenue & Net Profit History
Alpha Teknova, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $10.0M | +7.8% | $-4.8M | -47.7% |
| Q3 FY2025 | $10.5M | +9.2% | $-4.3M | -41.0% |
| Q2 FY2025 | $10.3M | +7.0% | $-3.6M | -34.7% |
| Q1 FY2025 | $9.8M | +5.4% | $-4.6M | -47.4% |
| Q4 FY2024 | $9.3M | +17.8% | $-5.7M | -61.7% |
| Q3 FY2024 | $9.6M | +17.2% | $-7.6M | -79.0% |
| Q2 FY2024 | $9.6M | -16.6% | $-5.4M | -55.8% |
| Q1 FY2024 | $9.3M | +1.9% | $-8.1M | -87.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $9.6M | $9.6M | $9.3M | $9.8M | $10.3M | $10.5M | $10.0M |
| YoY Growth | 1.9% | -16.6% | 17.2% | 17.8% | 5.4% | 7.0% | 9.2% | 7.8% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $120.8M | $115.4M | $124.1M | $118.8M | $114.0M | $110.5M | $107.6M | $103.6M |
| Liabilities | $37.4M | $36.4M | $36.8M | $36.4M | $35.4M | $34.4M | $35.0M | $34.8M |
| Equity | $83.4M | $78.9M | $87.3M | $82.4M | $78.6M | $76.1M | $72.7M | $68.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.6M | $-2.8M | $-2.1M | $-936000 | $-4.1M | $-2.1M | $-2.0M | $-462000 |